相关实验视频
Updated: May 8, 2025

08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
15.8K
达帕格利弗洛辛治疗减轻了2型糖尿病患者的脂肪肝
Xiuying Gao1, Chuanming Zhu2, Wei Zhu1
1Department of Endocrinology, Beijing Aerospace General Hospital, Beijing 100076, P.R. China.
Biomedical reports
|December 25, 2024
概括
在患有2型糖尿病和非酒精性脂肪性肝病的患者中,达帕格利弗洛辛显著降低了肝脂肪. 这种改善与更好的代谢健康和减少炎症相关.
科学领域:
- 内分泌学 在内分泌学.
- 肝病学 肝病学是一种肝病学.
- 代谢综合征是代谢综合征的一种.
背景情况:
- 非酒精性脂肪性肝病 (NAFLD) 在2型糖尿病 (T2DM) 患者中很普遍.
- 在T2DM患者中,有效的NAFLD管理策略至关重要.
研究的目的:
- 评估达帕格利弗洛辛在降低NAFLDT2DM患者肝脂肪含量的疗效.
- 分析达帕格利弗洛辛对生化和代谢参数的影响.
主要方法:
- 对35名NAFLDT2DM患者的临床数据的回顾性分析,这些患者接受了达帕格利弗洛辛治疗.
- 定量计算断层扫描 (qCT) 用于评估肝脏脂肪含量.
- 生物化学标志物,代谢参数和炎症性细胞因子在治疗前后被分析.
主要成果:
- 达帕格利弗洛辛治疗 (20周) 改善了血糖控制 (HbA1c,血葡萄糖) 和胰岛素抵抗.
- 肝脏脂肪含量显著降低 (16.1%至11.2%通过qCT,P<0.01).
- 在肝功能测试,内脏脂肪区域和炎症标志物 (hs-CRP,IL-6) 中观察到的改善.
结论:
- 达帕格利弗洛辛在NAFLD的T2DM患者中有效降低肝脂肪.
- 肝脂肪的减少与代谢参数和炎症性细胞因子的改善有关,包括体重,IL-6,甘油三和总胆固醇.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
117
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
117
Oral Hypoglycemic Agents: Biguanides and Glitazones
132
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
132
Glucagon-like Receptor Agonists
250
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
250
Diabetes: Management and Pharmacotherapy
203
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
203
Carbohydrate Metabolism
10.5K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.5K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
105
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
105

